Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA9 | Q16790 | 4/20 | 0.45 |
| ▸ | CA2 | P00918 | 3/20 | 0.45 |
| ▸ | CA12 | O43570 | 3/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.45 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.45 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.45 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.45 |
| ▸ | UGT1A7 | Q9HAW7 | 1/20 | 0.45 |
| ▸ | SLC22A11 | Q9NSA0 | 1/20 | 0.45 |
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
| ▸ | PPARA | Q07869 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26313790 | 0.87 | CA12 (0.41) | CA9CA2CA12RAB9ASMN1; SMN2 | |
| SCHEMBL26313787 | 0.85 | TP53 (0.43) | CA9CA2CA12RAB9ASMN1; SMN2 | |
| SCHEMBL26313780 | 0.82 | TP53 (0.47) | CA9CA2CA12RAB9ASMN1; SMN2 | |
| SCHEMBL26313789 | 0.81 | MMP2 (0.40) | PPARGPPARA | |
| SCHEMBL26313777 | 0.80 | TP53 (0.45) | CA9CA2CA12RAB9ASMN1; SMN2 | |
| SCHEMBL26313659 | 0.78 | PPARG (0.57) | PPARGPPARA | |
| SCHEMBL26313799 | 0.76 | CA9 (0.57) | CA9CA2CA12RAB9ASMN1; SMN2 | |
| SCHEMBL24162481 | 0.76 | CA9 (0.46) | CA9CA2CA12RAB9ASMN1; SMN2 | |
| SCHEMBL24162306 | 0.75 | CA9 (0.56) | CA9CA2CA12RAB9ASMN1; SMN2 | |
| SCHEMBL26313795 | 0.70 | TP53 (0.43) | CA9CA2CA12RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230257357-A1 | PROBENECID COMPOUNDS FOR THE TREATMENT OF INFLAMMASOME-MEDIATED LUNG DISEASE | BACAINN BIOTHERAPEUTICS, LTD. (KY) | 2023-08-17 | — | — | US | disclosed |
| CN-115989219-A | Probenecid compounds for the treatment of inflammasome-mediated pulmonary diseases | 贝凯恩生物医疗技术有限公司 | 2023-04-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257357-A1 | PROBENECID COMPOUNDS FOR THE TREATMENT OF INFLAMMASOME-MEDIATED LUNG DISEASE | NLRP3, PYCARD, NLRP1 | CA9 2197/4885CA2 3362/4885CA12 3513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.